Outlook Therapeutics reports FY24 EPS ($4.06) vs. ($4.72) last year

“Over the course of the past year, our team has continued to execute and progress the development of ONS-5010/LYTENAVA in Europe and the United States. Following the receipt of our first positive reimbursement decision worldwide for LYTENAVA from NICE in the United Kingdom, our team continues to make preparations for commercial launch in the UK and Germany, which is expected in the first half of calendar 2025,” commented Lawrence Kenyon, CFO and Interim CEO “We expect to receive the month 3 NORSE EIGHT efficacy data in January 2025 and are continuing preparations for the planned resubmission of our BLA in the first quarter of calendar 2025. We believe that 2025 holds significant opportunity for Outlook Therapeutics (OTLK) and we remain confident in the potential of ONS-5010/LYTENAVA to provide a meaningful impact globally for the treatment of wet AMD.”